Aurora Cannabis (ACB) Competitors

Aurora Cannabis logo
$6.31 -0.31 (-4.68%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$6.32 +0.01 (+0.08%)
As of 02/14/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACB vs. KNSA, GPCR, NRIX, ARQT, ARDX, INDV, ARVN, VIR, SNDX, and ANIP

Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Kiniksa Pharmaceuticals (KNSA), Structure Therapeutics (GPCR), Nurix Therapeutics (NRIX), Arcutis Biotherapeutics (ARQT), Ardelyx (ARDX), Indivior (INDV), Arvinas (ARVN), Vir Biotechnology (VIR), Syndax Pharmaceuticals (SNDX), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.

Aurora Cannabis vs.

Aurora Cannabis (NASDAQ:ACB) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Aurora Cannabis has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.

Kiniksa Pharmaceuticals has higher revenue and earnings than Aurora Cannabis. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$200.35M1.73-$48.62M$0.05126.23
Kiniksa Pharmaceuticals$270.26M5.27$14.08M-$0.14-140.99

In the previous week, Aurora Cannabis and Aurora Cannabis both had 9 articles in the media. Kiniksa Pharmaceuticals' average media sentiment score of 0.75 beat Aurora Cannabis' score of 0.33 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kiniksa Pharmaceuticals
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kiniksa Pharmaceuticals has a consensus price target of $36.60, suggesting a potential upside of 85.41%. Given Kiniksa Pharmaceuticals' higher probable upside, analysts clearly believe Kiniksa Pharmaceuticals is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.67
Kiniksa Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Aurora Cannabis has a net margin of 0.42% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Aurora Cannabis' return on equity of 0.59% beat Kiniksa Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis0.42% 0.59% 0.42%
Kiniksa Pharmaceuticals -2.36%-7.31%-5.95%

Aurora Cannabis received 213 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. However, 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote.

CompanyUnderperformOutperform
Aurora CannabisOutperform Votes
384
59.63%
Underperform Votes
260
40.37%
Kiniksa PharmaceuticalsOutperform Votes
171
65.02%
Underperform Votes
92
34.98%

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Aurora Cannabis and Kiniksa Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.

Get Aurora Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACB vs. The Competition

MetricAurora CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$346.17M$1.21B$5.87B$9.17B
Dividend YieldN/AN/A5.27%3.99%
P/E Ratio126.2323.1016.4414.51
Price / Sales1.735.72467.0677.77
Price / Cash27.9710.8846.0638.90
Price / Book0.791.917.275.05
Net Income-$48.62M-$53.22M$3.19B$222.81M
7 Day Performance-4.54%2.06%1.67%1.29%
1 Month Performance63.90%3.83%4.11%1.52%
1 Year Performance60.56%-7.80%22.09%16.53%

Aurora Cannabis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACB
Aurora Cannabis
0.6798 of 5 stars
$6.31
-4.7%
N/A+60.6%$346.17M$200.35M126.231,073
KNSA
Kiniksa Pharmaceuticals
3.6058 of 5 stars
$19.60
+0.6%
$36.60
+86.7%
-1.0%$1.42B$270.26M-139.99220
GPCR
Structure Therapeutics
2.7697 of 5 stars
$24.29
-11.4%
$81.29
+234.6%
-46.7%$1.39BN/A-32.82136Short Interest ↓
NRIX
Nurix Therapeutics
2.2429 of 5 stars
$18.01
-4.6%
$31.12
+72.8%
+78.2%$1.37B$54.55M-6.23300
ARQT
Arcutis Biotherapeutics
2.7865 of 5 stars
$11.59
-0.2%
$16.60
+43.2%
+37.4%$1.36B$59.61M-6.47150
ARDX
Ardelyx
3.7479 of 5 stars
$5.57
-0.2%
$9.42
+69.1%
-36.0%$1.32B$124.46M-18.5790Short Interest ↑
INDV
Indivior
2.5632 of 5 stars
$9.54
-0.4%
$16.00
+67.7%
-44.0%$1.32B$1.09B-238.441,164Short Interest ↑
Positive News
ARVN
Arvinas
2.8611 of 5 stars
$18.97
+1.4%
$61.45
+224.0%
-65.0%$1.30B$78.50M-4.06420Earnings Report
Short Interest ↑
Analyst Revision
VIR
Vir Biotechnology
4.1805 of 5 stars
$9.38
-4.7%
$34.83
+271.4%
-5.9%$1.29B$86.18M-2.39580
SNDX
Syndax Pharmaceuticals
3.8217 of 5 stars
$15.13
-2.5%
$36.20
+139.3%
-33.6%$1.29B$16M-4.17110
ANIP
ANI Pharmaceuticals
4.4487 of 5 stars
$59.59
-1.6%
$77.71
+30.4%
-1.3%$1.25B$486.82M-108.35600

Related Companies and Tools


This page (NASDAQ:ACB) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners